Memantine Hydrochloride Tablet
Product Images NDC 71610-011

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71610-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10mg (71610 0011 18)

Memantine HCl 10 mg tablets label from Aphena Pharma Solutions - Tennessee, LLC. The label states the quantity as 3000 tablets, includes NDC 71610-0011-18, provides temperature storage information, and notes the product is for prescription use only (Rx Only).*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (Mem00 0000 01)

Chemical structure of memantine hydrochloride, showing a tricyclic cage-like amine structure with attached hydrochloride (HCl) and methyl groups. The image depicts the molecular arrangement relevant to the active ingredient memantine hydrochloride.*

FDA Label Image

Figure 1 (Mem00 0000 02)

A line graph depicting the mean change from baseline in ADCS-ADL score over 28 weeks of treatment for memantine hydrochloride (NAMENDA) versus placebo. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows the mean ± SEM change from baseline. Two lines with error bars indicate clinical improvement or decline for NAMENDA and placebo groups.*

FDA Label Image

Figure 2 (Mem00 0000 03)

A line graph comparing cumulative percentage of patients over changes in ADCS-ADL from baseline, showing two plots labeled Placebo and NAMENDA (memantine hydrochloride). The x-axis represents ADCS-ADL change from baseline, and the y-axis represents cumulative percentage of patients.*

FDA Label Image

Figure 3 (Mem00 0000 04)

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment for two groups: Placebo and NAMENDA. The graph illustrates clinical improvement and decline, with error bars showing variability at each time point.*

FDA Label Image

Figure 4 (Mem00 0000 05)

A cumulative percentage graph depicting the percentage of patients on the vertical axis and SIB change from baseline on the horizontal axis, comparing two groups: Placebo (black squares) and NAMENDA (open circles). The chart shows the distribution of patient responses relative to baseline changes in SIB scores.*

FDA Label Image

Figure 5 (Mem00 0000 06)

A line graph showing the mean change from baseline in the ADAS-cog score over 24 weeks of treatment comparing placebo/donepezil and NAMENDA/donepezil. The graph displays two lines with error bars, illustrating clinical improvement and decline trends over time.*

FDA Label Image

Figure 6 (Mem00 0000 07)

A cumulative percentage of patients line graph comparing placebo/Donepezil and NAMENDA/Donepezil treatments. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients, illustrating patient response distribution for each treatment group.*

FDA Label Image

Figure 7 (Mem00 0000 08)

A line graph showing the mean change from baseline in SIB score over 24 weeks of treatment. It compares two groups: one receiving placebo plus donepezil and the other receiving memantine plus donepezil. The graph shows trends of clinical improvement and decline during the study period, with error bars representing standard error of the mean.*

FDA Label Image

Figure 8 (Mem00 0000 09)

A line graph depicting the cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline. Two data sets are shown: Placebo/Donepezil and NAMENDA/Donepezil, represented by filled squares and open circles respectively, illustrating the efficacy comparison between the two treatments.*

FDA Label Image

Figure (Mem00 0000 10)

Memantine HCl Oral Solution 2 mg/mL packaging including a boxed carton, a brown glass bottle with a white label and a measuring syringe with a plunger and a cap, all labeled by Aphena Pharma Solutions - Tennessee, LLC. The carton and bottle front labels display the product name, strength, and dosage form.*

FDA Label Image

Figure (Mem00 0000 11)

An instructional illustration showing hands opening a sterile packaging containing a syringe and needle. The image depicts the removal of the needle cap prior to use, demonstrating aseptic technique for preparation of an injectable drug.*

FDA Label Image

Figure (Mem00 0000 12)

Memantine HCl Oral Solution in a dark glass bottle with a child-resistant cap shown being opened by a hand. The label includes the proprietary name Memantine HCl, the dosage form oral solution, and the labeler Aphena Pharma Solutions - Tennessee, LLC. The NDC number 71610-011 is visible on the label.*

FDA Label Image

Figure (Mem00 0000 13)

An illustration shows a hand using a dropper to dispense a liquid from a dark glass bottle labeled "Memantine HCl Oral Solution." The bottle has a white label with text indicating the product name and concentration. The image demonstrates the method for administering the oral solution form of memantine hydrochloride.*

FDA Label Image

Figure (Mem00 0000 14)

An instructional illustration showing a hand holding a medication bottle while another hand is removing or placing the bottle cap. An arrow indicates the direction of the cap removal or placement. The image demonstrates proper handling of an oral liquid medication bottle.*

FDA Label Image

Figure (Mem00 0000 15)

An instructional illustration showing how to open a child-resistant cap on a bottle of Memantine HCl Oral Solution, 10 mg/1. The image includes a zoomed inset of the cap mechanism being lifted by a hand, demonstrating proper opening technique. The bottle label displays the product name, dosage form, and labeler Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Figure (Mem00 0000 16)

An instructional illustration showing two hands preparing a medication. One hand holds a black bottle with a flip-top cap open, while the other hand uses a syringe to withdraw liquid from the bottle. No text or labels are visible on the bottle.*

FDA Label Image

Figure (Mem00 0000 17)

An instructional illustration showing a person holding a small dark bottle with a cap attached while inserting a syringe plunger upwards into the bottle's opening. The image demonstrates the proper technique to draw liquid from the bottle using a syringe.*

FDA Label Image

Figure (Mem00 0000 18)

An illustration of a hand holding a syringe filled with liquid above a small vial with a screw cap removed, suggesting preparation for an injection.*

FDA Label Image

Figure (Mem00 0000 19)

An instructional illustration showing a man opening his mouth to receive an oral medication, with a gloved hand placing a tablet on his tongue.*

FDA Label Image

Figure (Mem00 0000 20)

An instructional illustration showing hands opening a dark glass bottle with a child-resistant cap. The label on the bottle displays the text 'memantine hydrochloride'. The person uses one hand to hold the bottle steady and the other hand to push down and twist the cap to open.*

FDA Label Image

Figure (Mem00 0000 21)

An instructional illustration showing a pair of hands stirring a tablet dissolving in a glass of liquid using a stirring motion indicated by a double-headed arrow.*

FDA Label Image

Figure (Mem00 0000 22)

Memantine HCl Oral Solution 2 mg/mL in a clear bottle with a gray child-resistant cap and dosing syringe attached. Label shows the product name, concentration, volume (possibly 15 mL), and the labeler Aphena Pharma Solutions - Tennessee, LLC. The label includes a National Drug Code (NDC) and other regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.